Fetal Hemoglobin Reactivation: Exploring Natural Therapies for Beta-Thalassemia and Sickle Cell Anemia
Received Date: May 01, 2023 / Published Date: May 29, 2023
Abstract
Fetal hemoglobin (HbF) is a potent genetic modifier, and the γ-globin gene induction has proven to be a sustainable therapeutic approach for the management of β-thalassemia. In this study, we have evaluated the HbF induction ability of A. vasica in vitro and in vivo, and the identification of potential therapeutic compounds through a bioassay-guided approach. In vitro benzidine-Hb assay demonstrated strong erythroid differentiation of K562 cells by A. vasica extracts. Subsequently, an in vivo study with an aqueous extract of A. vasica showed significant induction of the γ-globin gene and HbF production. By examining the action mechanisms of the HbF-inducing agents, various studies have suggested that despite the ability of stimulating HbF production, the chemotherapeutic agents could not be practically applied for treating β - hemoglobinopathies, especially β -thalassemia, due to the their cytotoxicity and growth-inhibitory effect. Owing to this therapeutic obstacle, much effort has been put on identifying new HbF-inducing agents from the natural world with the combination of efficacy, safety, and ease of use.
Citation: Stokes W (2023) Fetal Hemoglobin Reactivation: Exploring NaturalTherapies for Beta-Thalassemia and Sickle Cell Anemia. J Tradit Med Clin Natur,12: 377.
Copyright: © 2023 Stokes W. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 527
- [From(publication date): 0-2023 - Aug 17, 2024]
- Breakdown by view type
- HTML page views: 469
- PDF downloads: 58